These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 9127622)

  • 21. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
    Bown RL
    Int J Clin Pract; 2002 Mar; 56(2):132-9. PubMed ID: 11926700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
    Lazzaroni M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing acid suppression for treatment of acid-related diseases.
    Hunt RH; Cederberg C; Dent J; Halter F; Howden C; Marks IN; Rune S; Walt RP
    Dig Dis Sci; 1995 Feb; 40(2 Suppl):24S-49S. PubMed ID: 7859582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New therapeutic options in the treatment of GERD and other acid-peptic disorders. Based on a presentation by Duane D. Webb, MD, FACG.
    Am J Manag Care; 2000 May; 6(9 Suppl):S467-75. PubMed ID: 10977486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term management of gastroesophageal reflux disease and its complications.
    Richter JE
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):30S-34S; discussion 34S-35S. PubMed ID: 9127624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing medical therapy for gastroesophageal reflux disease: state of the art.
    Katz PO
    Rev Gastroenterol Disord; 2003; 3(2):59-69. PubMed ID: 12776003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological control of gastric acid secretion.
    Zfass AM; McHenry L; Sanyal AJ
    Gastroenterologist; 1993 Mar; 1(1):83-7. PubMed ID: 8049882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?
    Armstrong D
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():19-26; discussion 38-9. PubMed ID: 15456460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
    Andersson K; Carlsson E
    Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds.
    Scarpignato C; Pelosini I
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic approaches to reflux disease, focusing on acid secretion.
    Kinoshita Y; Adachi K; Fujishiro H
    J Gastroenterol; 2003 Mar; 38 Suppl 15():13-9. PubMed ID: 12698865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: acid-related disease--what are the unmet clinical needs?
    Katz PO; Scheiman JM; Barkun AN
    Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():9-22. PubMed ID: 16700899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [25 years of gastric acid blockers].
    Lamers CB
    Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2501-4. PubMed ID: 10627749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings.
    Tytgat GN
    Yale J Biol Med; 1999; 72(2-3):219-26. PubMed ID: 10780584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of gastric acid secretion in health and disease.
    Schubert ML; Peura DA
    Gastroenterology; 2008 Jun; 134(7):1842-60. PubMed ID: 18474247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of antacids in the management of disorders of the upper gastrointestinal tract. Review of clinical experience 1975-1985.
    Lanza FL; Sibley CM
    Am J Gastroenterol; 1987 Dec; 82(12):1223-41. PubMed ID: 3318401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic approaches to healing esophagitis.
    Boyce HW
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):22S-27S; discussion 27S-29S. PubMed ID: 9127623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.
    Howden CW; Burget DW; Hunt RH
    Scand J Gastroenterol Suppl; 1994; 201():79-82. PubMed ID: 8047830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding?
    Geus WP
    Scand J Gastroenterol Suppl; 2000; (232):10-20. PubMed ID: 11232484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.